FOLD Stock Price Today (April 2026) — Amicus Therapeutics Inc Analysis & Key Metrics 2026-04-27
Amicus Therapeutics Inc (FOLD) is trading at $14.49, up 0.00% today (as of April 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $14.50 (0.1% upside).
- Volatility remains elevated (93.50% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (23.70% YoY) alongside significant competitive pressures.
FOLD Stock Analysis: Key Metrics & Valuation (April 2026)
Concise, actionable data for investors
Amicus Therapeutics Inc - Historical Price & Volume
Market Cap
Enterprise Value: $4.70B
P/E Ratio
Forward P/E: 17.69
Revenue Growth
Year over Year
Analyst Target
+0.1% upside potential
Key Investor Questions About FOLD
What investors need to know before buying
Based on current market data, FOLD presents a overbought technical setup with caution warranted fundamentals.
- Technicals say: Overbought (RSI 74.69)
- Fundamentals say: Caution warranted (high leverage concerns)
FOLD's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for FOLD investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $442.36M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, FOLD stock traded between $5.51 and $14.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 93.50% annualized volatility and β=0.62, the stock exhibits low sensitivity to market moves—making FOLD suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth accelera
BioMarin acquires Amicus Therapeutics for $4.8bn
With the acquisition, BioMarin adds Galafold for Fabry disease and Pombiliti+Opfolda for Pompe disease.
CIBRA Capital Buys Stake in Allied Gold Stock
Allied Gold Corporation operates a diversified mining business with core assets across Africa, producing and selling gold and silver.
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.
Here is Why BioMarin (BMRN) is Projected to Rally
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 best stocks that recently issued new debt. On March 11, Bank of America Securities reduced its price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) from $97 to $85. The firm maintained a Buy rating on the stock, which now yields an adjusted upside of almost 54% despite […]
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return
Why Amicus Therapeutics is on investors’ radar today Amicus Therapeutics (FOLD) has drawn attention after recent share performance data highlighted a 71% total return over the past year, prompting closer scrutiny of how its rare disease portfolio and fundamentals align with current pricing. See our latest analysis for Amicus Therapeutics. While the recent 1-day and 7-day share price returns of around 0% suggest a pause, the 1-year total shareholder return of about 71% points to strong...
Why Is Adma Biologics (ADMA) Down 45.4% Since Last Earnings Report?
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
On Thursday, Tarsus Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 76 to 82. Looking For The Best Stocks To Buy And Watch? Start Here IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score.
Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Frequently Asked Questions
Common investor questions about Amicus Therapeutics Inc
Amicus Therapeutics Inc (FOLD) is currently trading at $14.49. The RSI (14-day) is at 74.7, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $14.50 implies 0.1% upside from current levels. Volatility is high at 93.5% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amicus Therapeutics Inc (FOLD): The trailing P/E ratio is -161.00, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 17.69. Price-to-Book is 16.43. Price-to-Sales is 7.17. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 5 analysts covering FOLD, the consensus price target is $14.50. This represents a 0.1% upside from the current price of $14.49. The range spans from a low target of $14.50 to a high target of $14.50, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Amicus Therapeutics Inc (FOLD) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Amicus Therapeutics Inc (FOLD) investors include: 1. High volatility (93.5% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (D/E ratio of 161.30) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amicus Therapeutics Inc's (FOLD) current debt and financial health profile: Total debt stands at $442.36M. The debt-to-equity ratio is 161.30, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 2.84, indicating strong short-term liquidity. The quick ratio is 1.72. The company holds $293.54M in cash and equivalents. Free cash flow is positive at $47.84M, providing a cushion for debt servicing and shareholder returns.